Barclays Downgrades Moderna (NASDAQ:MRNA) to Equal Weight
Moderna (NASDAQ:MRNA – Get Free Report) was downgraded by research analysts at Barclays from an “overweight” rating to an “equal weight” rating in a research note issued on Tuesday, Marketbeat reports. They presently have a $45.00 target price on the stock, down from their previous target price of $111.00. Barclays‘s price objective indicates a potential […]
More Stories
5 Million Christmas Lights Illuminate 19th Century Ohio Grist Mill
By Jeff Louderback CLIFTON, Ohio—With one flip of a switch, 5 million lights transform one of the country’s largest remaining...
Pentagon Partners With xAI Service for Military’s Growing Artificial Intelligence Toolset
By Ryan Morgan The U.S. military is set to expand its artificial intelligence (AI) toolset in a new partnership with...
DOGE Says 14 Contracts Worth $190 Million Canceled
By Tom Ozimek The Department of Government Efficiency (DOGE) said federal agencies terminated or scaled back 14 additional contracts over...
Transportation Department to Spend Nearly $1 Billion Toward Road Safety
By Naveen Athrappully Transportation Secretary Sean P. Duffy has announced almost $1 billion in funding to “make roads safer for...
Wyoming Congresswoman Who Ousted Liz Cheney Launches Senate Bid
By Bill Pan Rep. Harriet Hageman (R-Wyo.) is running for the Wyoming Senate seat being vacated by Republican Sen. Cynthia...
US Consumers Grow More Optimistic About Future Finances, Recession Fears Retreat
By Tom Ozimek U.S. consumers grew more hopeful about their future financial prospects in December and edged away from worst-case...